

Levofloxacin and Ibuprofen Leading to Steven Johnson Syndrome: A Dermatological Emergency

Muhammad Raheel Zafar, Mohsin Ahmed, Muhammad Sharjeel Sabir

Department of Medicine Benazir Bhutto Hospital and Rawalpindi Medical University .

Introduction:

Stevens-Johnson syndrome is a rare, serious disorder of your skin and mucous membranes. It's usually a reaction to a medication or an infection. Often, it begins with flu-like symptoms, followed by a painful red or purplish rash that spreads and blisters. Then the top layer of the affected skin dies, sheds and then heals. Stevens-Johnson syndrome is a medical emergency that usually requires hospitalization.¹ Treatment focuses on eliminating the underlying cause, controlling symptoms and minimizing complications as skin regrows. Recovery after Stevens-Johnson syndrome can take weeks to months, depending on the severity of condition. If it was caused by a medication, you'll need to permanently avoid that drug and others closely related to it.^{2,3}

Case Report

A 43 year old patient, came to emergency department in Benazir Bhutto hospital. Patient was conscious with a GCS of 15 by 15 and normal vitals. He complained of rash and itching all over body. On history taking, patient told that he went to TB hospital in Rawalpindi for TB workup as advised by some doctor in Lahore. TB workup came negative and doctor prescribed levofloxacin, ibuprofen and an expectorant for LRTI. He took 1st dose of medications 3 days back and after taking the dose, he started to develop ulcers in mouth and lips and genital areas with multiple blisters and bullae on legs and arms (Figure 1). Patient discontinued the medication. He has no known comorbidities. He had no other significant medical or social history. On examination, patient was afebrile with a BP of 120 by 80, pulse 80 per min respiratory rate of 16 per min. There were multiple blisters and bullae on legs and arms with desquamating lesions on lips. There were ulcers in mouth and genital areas. Rest of systemic examination was unremarkable.

Patient was retained in ER and IV line was maintained and was given injection Avil and Solcortif 250mg, injection calamox, injection ceftriaxone and injection zantac. Subsequently, patient was shifted to medical unit II of BBH for diagnosis and further

management. In ward, blood tests were taken and were found within normal limits. Dermatology consultation was taken and patient diagnosed of Steven Johnson Syndrome on basis of history and skin lesions and skin biopsy which showed less than 10 percent involvement of skin. Treatment given to patient was tablet deltacortil (5mg) 4+4; Kenalog Orabase (triamcinolone acetonide) BD on affected areas; Daktarin oral gel (Miconazole) BD on affected areas; Paraffin Guazes BD on affected areas; Inj calamox (Coamoxiclav) 1.2 g XTDS; Hydrex Emollient. Addition of unnecessary medications to treatment plan was prohibited. Patient remained on these medications for a week in ward and his condition improved. He was advised not to take these medications in future and discharged after a week since his admission. He was followed up in OPD and his condition further improved.



Figure 1: Steven Johnson Syndrome - Ulcers on lips and oral cavity

Discussion

Steven Johnson Syndrome (SJS) is a rare condition, with a reported incidence of around 2.6 to 6.1 cases per million people per year. The condition is more common in adults than in children.⁵ Women are affected more often than men. SJS usually begins with fever, sore throat, and fatigue, which is commonly misdiagnosed and therefore treated with antibiotics. Ulcers and other lesions begin to appear in the mucous membranes, almost always in the mouth and lips, but also in the genital and anal regions. Those in the

mouth are usually extremely painful and reduce the patient's ability to eat or drink occurring at a two to one ratio.⁶

SJS is thought to arise from a disorder of the immune system. The immune reaction can be triggered by drugs or infections. Genetic factors are associated with a predisposition to SJS.⁷SJS may be caused by adverse effects of the drugs vancomycin, allopurinol, valproate, levofloxacin, diclofenac, etravirine, isotretinoin, fluconazole, valdecoxib, sitagliptin, oseltamivir, penicillins, barbiturates, sulfonamides, phenytoin, azithromycin, oxcarbazepine, zonisamide, modafinil, lamotrigine, nevirapine, pyrimethamine, ibuprofen, ethosuximide, carbamazepine, bupropion, telaprevir, and nystatin.⁸

The second most common cause of SJS is infection, particularly in children. This includes upper respiratory infections, otitis media, pharyngitis, and Epstein-Barr virus, Mycoplasma pneumoniae and Cytomegalovirus infection.⁹ Diagnosis is based on less than 10 percent involvement of skin. If it is more than 30 percent it is toxic epidermal necrolysis. SJS constitutes a dermatologic emergency. Treatment consists of supportive care and corticosteroids.¹⁰

References

1. Darlenski R, Kazandjieva J, Tsankov N. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS. *Clinics in Dermatology*. 2015;33:538.
2. Ask Mayo Expert. Nonimmunoglobulin e-mediated (non-IgE) drug sensitivity. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2016.
3. David A. **Wetter**, MD and Michael J. Clinical, etiologic and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. *Mayo Clinic Proceedings*. 2010;85:131.
4. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. *Critical Care Medicine*. 2011;39:1521.
5. Tangamornsuksan Wl. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. *JAMA Dermatology*. 2013;149:1025.
6. Yip VL. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A systematic review. *Clinical Pharmacology and Therapeutics*. 2012;92:757.
7. Nirken MH. Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis. <http://www.uptodate.com/home>. Accessed Jan. 19, 2017.
8. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E. Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae. <http://www.uptodate.com/home>. Accessed Jan. 19, 2017.
9. Silva T, Neves J, Casimiro A, Varandas L. Stevens-Johnson syndrome, toxic epidermal necrolysis. In: *Dermatology: An Illustrated Colour Text*. 6th ed. Edinburgh, U.K.: Elsevier; 2017. <https://www.clinicalkey.com>. Accessed Jan. 19, 2017.
10. FDA drug safety communication: FDA warns of rare but serious skin reactions with the pain reliever/fever reducer acetaminophen. U.S. Food and Drug Administration. <http://www.fda.gov/drugs/drugsafety/ucm363041.htm>. Accessed Jan. 19, 2017.